Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472958 | 1.00 | IMPDH2 (1.00) | IMPDH2AAK1 | |
| SCHEMBL1473911 | 1.00 | IMPDH2 (1.00) | IMPDH2AAK1 | |
| SCHEMBL1474552 | 0.98 | IMPDH2 (0.95) | IMPDH2AAK1 | |
| SCHEMBL1473719 | 0.92 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1473715 | 0.92 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1476068 | 0.92 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1474058 | 0.90 | IMPDH2 (0.82) | IMPDH2AAK1 | |
| SCHEMBL1474074 | 0.89 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1474138 | 0.89 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1474064 | 0.89 | IMPDH2 (1.00) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448187-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1448187-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003047512-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | claimed |
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | claimed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| EP-1786415-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-05-23 | — | — | EP | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885AAK1 4637/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885AAK1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.